Geldanamycin derivative and method of treating cancer same

A technology of geldanamycin and derivatives, applied in the field of geldanamycin

Inactive Publication Date: 2004-03-24
UNITED STATES OF AMERICA
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, no known geldanamycin compounds or derivatives thereof have shown in vivo activity when administered orally

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Geldanamycin derivative and method of treating cancer same
  • Geldanamycin derivative and method of treating cancer same
  • Geldanamycin derivative and method of treating cancer same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] This example shows the in vivo activity of compounds of the invention compared to geldanamycin derivatives of similar structure.

[0067] Compounds A-C were subjected to hollow fiber assays as described above. Compounds A and B were mixed with saline and Tween 80 (0.05%) to give two dose levels of 75 mg / kg / dose and 50 mg / kg / dose, respectively. Compound C was also mixed with saline and Tween 80 (0.05%) to give two dose levels of 20 mg / kg / dose and 13.4 mg / kg / dose, respectively. Optimal dosage levels were determined from previous toxicology studies, therefore, the dosage used represents the upper limit that can be administered to the host without inducing toxic effects. All three compounds were administered by intraperitoneal injection once daily for four days. After 4 days, the hollow fibers were removed from the mice and the MTT assay described above was performed. The HFA score for each compound was determined from the calculation of percent cell growth inhibition [(...

Embodiment 2

[0071] This example shows the oral in vivo activity of the compounds of the invention.

[0072]As described above, hollow fiber detection was performed using compound B of the present invention. Compound B was mixed with water to give two dosage levels of 75 mg / kg / dose and 50 mg / kg / dose, respectively. Compound B was then administered orally (PO) once a day for four days. After 4 days, the hollow fibers were removed from the mice and the MTT assay described above was performed. The HFA score for each compound was determined from the calculation of percent cell growth inhibition [(1-(% treated net growth / % control net growth))*100], as shown in Table 2.

[0073] compound

[0074] According to the above results, Compound B of the present invention exhibited significant in vivo anticancer activity in oral administration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administrering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

Description

[0001] Cross References to Related Applications [0002] This patent application claims priority to US Provisional Patent Application 60 / 280,078, filed March 30,2001. technical field [0003] The present invention relates to geldanamycin, more specifically to new geldanamycin derivatives, pharmaceutical compositions thereof, and methods for preventing and treating cancer using these derivatives. Background technique [0004] The ErbB2 gene product, which is a member of the ErbB family of tyrosine kinase receptors, is believed to play an important role in malignant tumor cells. Studies have shown that overexpression of ErbB2 causes cellular transformation and tumorigenesis, and in vitro experiments have shown that ErbB2 is required to induce tumor cell invasion by other members of the ErbB family. The benzoquinones ansamycin and geldanamycin have antitumor activity in vivo and have been shown to cause rapid depletion of ErbB2 protein levels. Geldanamycin is a specific inhib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/395A61P35/00A61P43/00C07D225/06
CPCC07D225/06A61P35/00A61P43/00
Inventor 肯尼思·M·斯纳德B·拉奥·维什努维吉拉梅林达·G·霍林希德爱德华·A·索维莱
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap